H.R. 5376 · 118th Congress · Health

Share the Savings with Seniors Act

Died in committee580 words Introduced Sep 8, 2023 · Latest action Dec 17, 2024

How far it has goneStopped at 2 of 6 · Died in committee
  1. IntroducedSep 8, 2023 Done
  2. CommitteeDied Jan 3, 2025 Stopped here
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill limits cost-sharing for chronic care drugs under the Medicare prescription drug benefit. Chronic care drugs include blood glucose regulators other than insulin, anticoagulants, and other categories of drugs as specified in the bill.

Specifically, for costs below the annual deductible, the bill caps cost-sharing for chronic care drugs at the net price of the drug (i.e., the negotiated price net of all manufacturer price concessions); for costs above the annual deductible and below the annual out-of-pocket threshold, cost-sharing must be based on a percentage of the drug's net price (if cost-sharing for that drug is tied to the price or cost of the drug).

Congressional Research Service · summary of “Introduced in House” version · Sep 8, 2023

Who lobbies on it

147 organizations · 883 filings · Q3 2023–Q4 2024

These 147 organizations’ PACs gave $989K to 7 of the 9 members sponsoring or cosponsoring H.R. 5376 in the 2025–26 election cycle.

See who got it, from which PACs, and how they compare to the rest of the House → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. National Association of Realtors 6 of 6 quarters
    “Issues related to SALT and pass-through; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Issues related to tax reform.”

    $86.1M lobbying spend in 2024, all issuesQ4 2024 filing

  2. Chamber of Commerce of the U.s.a. 6 of 6 quarters
    “…H.R. 5376, Inflation Reduction Act of 2022 Potential legislation similar to S. 1416, Affordable Prescriptions for Patients Act of 2019 Potential legislation regarding revisions to the tech transfer framework established under the Bayh-Dole Act (P.L. 96-517) Potential legislation amending the Inflation Reduction Act…”

    $74.5M lobbying spend in 2024, all issuesQ4 2024 filing

  3. Pharmaceutical Research and Manufacturers of America 6 of 6 quarters
    “Implementation of H.R.5376 Inflation Reduction Act. H.R.7174 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R.10545 - American Relief Act, 2025 as it relates to PBM reform.”

    $31.0M lobbying spend in 2024, all issuesQ4 2024 filing

144 more organizations, every filingPROUpgrade

Organizations that named H.R. 5376 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

4 actions · newest first
  1. Dec 17, 2024Referred to the Subcommittee on Health.
  2. Sep 15, 2023Referred to the Subcommittee on Health.
  3. Sep 8, 2023Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. Sep 8, 2023Introduced in House